|
Duration of variable-length baseline period (years), mean (SD)
|
3.4 (1.8)
|
3.4 (1.9)
|
3.0 (1.8)
|
3.9 (1.8)
|
|
Age at index date (years), mean (SD)
|
45.6 (16.5)
|
46.5 (17.1)
|
45.5 (15.4)
|
45.2 (17.4)
|
|
Gender, n (%)
|
|
Female
|
113 (50.2)
|
22 (51.2)
|
49 (53.3)
|
42 (46.7)
|
|
Male
|
112 (49.8)
|
21 (48.8)
|
43 (46.7)
|
48 (53.3)
|
|
12-month baseline Charlson comorbidity score, mean (SD)
|
0.7 (1.3)
|
0.5 (1.0)
|
0.7 (1.5)
|
0.7 (1.2)
|
|
Prior biologic use, n (%)
|
|
Adalimumab
|
101 (44.9)
|
0 (0.0)
|
44 (47.8)
|
57 (63.3)
|
|
Infliximab
|
87 (38.7)
|
0 (0.0)
|
28 (30.4)
|
59 (65.6)
|
|
Golimumab
|
27 (12.0)
|
0 (0.0)
|
4 (4.4)
|
23 (25.6)
|
|
Vedolizumab
|
90 (40.0)
|
0 (0.0)
|
16 (17.4)
|
74 (82.2)
|
|
Number of unique biologics, n (%)
|
|
0
|
43 (19.1)
|
43 (100.0)
|
NA
|
NA
|
|
1
|
92 (40.9)
|
NA
|
92 (100.0)
|
NA
|
|
2
|
64 (28.4)
|
NA
|
NA
|
64 (71.1)
|
|
Vedolizumab + TNFi
|
49 (21.8)
|
NA
|
NA
|
49 (54.4)
|
|
TNFi + TNFi
|
15 (6.7)
|
NA
|
NA
|
15 (16.7)
|
|
≥ 3
|
26 (11.6)
|
NA
|
NA
|
26 (28.9)
|
